Literature DB >> 22124453

No appetite efficacy of a commercial structured lipid emulsion in minimally processed drinks.

H J Smit1, E Keenan, E M R Kovacs, S A Wiseman, D J Mela, P J Rogers.   

Abstract

BACKGROUND/
OBJECTIVES: Fabuless (Olibra) is a commercially structured lipid emulsion, claimed to be a food ingredient that is effective for food intake and appetite reduction. The present study assessed its efficacy in a yoghurt-based mini-drink undergoing low or minimal food manufacturing (thermal and shear) processes. SUBJECTS/
METHODS: Study 1: Twenty-four healthy volunteers (16 female, 8 male; age: 18-47 years; body mass index (BMI): 17-28 kg m(-2)) took part in a randomised, placebo-controlled, double-blind parallel crossover trial. Consumption of a minimally processed 'preload' mini-drink (containing two different doses of Fabuless or a control fat) at 2 h after breakfast was followed by appetite and mood ratings, and food intake measured in ad libitum meals at 3 and 7 h post consumption of the preload. Study 2: As Study 1 (16 female, 8 male; age: 20-54 years; BMI: 21-30 kg m(-2)). A chilled, virtually unprocessed, preload breakfast mini-drink (containing minimally processed Fabuless or a control fat) was provided 5 min after a standardised breakfast, followed by appetite and mood ratings, and food intake measured in ad libitum meals at 4 and 8 h post consumption of the preload.
RESULTS: The structured lipid emulsion tested had no significant effect on the primary measures of food intake or appetite.
CONCLUSIONS: Even when exposed to minimal food-manufacturing conditions, Fabuless showed no efficacy on measures of appetite and food intake.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22124453     DOI: 10.1038/ijo.2011.237

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  2 in total

Review 1.  Reduced-fat foods: the complex science of developing diet-based strategies for tackling overweight and obesity.

Authors:  David J McClements
Journal:  Adv Nutr       Date:  2015-05-15       Impact factor: 8.701

2.  An analysis of the "Effect of Olibra: a 12-week randomized control trial and a review of earlier studies".

Authors:  Martina Heer
Journal:  J Diabetes Sci Technol       Date:  2012-05-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.